R&D Leadership

our people

MR&D_Header_900x390_R&D Leadership

Our Medical R&D leaders have individually and collectively made a academic contributions to clinical, biostatistical and translational research that are driving the evolution of both clinical trial design and the treatment of chronic inflammatory diseases. We are tackling the most difficult unmet research and medical needs and providing solutions to improve human health. Client access to and collaboration with these academic experts differentiates Alimentiv from traditional Contract Research Organizations.

Dot

R&D Leadership

Guangyong (GY) Zou

PhD - Biostatistician Director

Guangyong (GY) Zou

PhD - Biostatistician Director

After completing PhDs in Biostatistics and Plant Science from the University of Connecticut, GY joined Alimentiv in September 2002. He is also a full professor at Western University.

Background

GY oversees statistical support for academic R&D programs, as well as Alimentiv IBD clinical research.

He has over 20 years of experience designing and analyzing clinical trials, including cluster randomization trials. His research has primarily focused on development and evaluation of statistical methods for medical research. At Alimentiv, he’s also researching endpoint development and validation, larger-scale effectiveness research and strategy trials.

He has published over 150 peer-reviewed articles, many of which have impacted medical and epidemiologic research. A single-authored 2004 article on regression models for estimating risk ratios has already received close to 3,000 citations.

Achievements

He wrote a 2004 paper on estimation of risk ratios that’s been cited close to 5,000 times, and a 2012 paper the company uses to design reliability studies.

Ethos

“Results are only as good as the statistical methodology used to obtain them. My goal is to continuously create good statistical methodology for medical research.”


Niels Vande Casteele

Director Precision Medicine

Niels Vande Casteele

Director Precision Medicine

Dr. Vande Casteele established the precision medicine group where he oversees the development, validation and operationalization of clinical pharmacology & translational medicine research tools to ascertain efficient drug development.

 

Background

Dr. Vande Casteele holds a Bachelor in Pharmaceutical Sciences and Masters in Drug Design and Development from the University of Leuven, Belgium. He performed research in the field of Molecular Biology at the Institute of Medical Sciences, University of Aberdeen, Scotland, and in the field of Immunology at Sanquin, University of Amsterdam, the Netherlands. He obtained his Ph.D. in Pharmaceutical Sciences entitled “Optimizing anti-TNF therapy in inflammatory bowel disease patients, a step towards personalized dosing” at the University of Leuven, Belgium.

 

Dr. Vande Casteele currently holds an appointment as Assistant Professor of Medicine at the University of California San Diego, United States, where he teaches a course on Biologics and Biosimilars Drug Development. His main research efforts focus on clinical pharmacology and translational medicine of small and large molecules used in the treatment of chronic inflammatory diseases, with an emphasis on characterizing pharmacokinetics and pharmacodynamics in relation to treatment outcomes in clinical practice and drug development.

 

Achievements

Dr. Vande Casteele has published over 100 peer reviewed research articles and book chapters; has given over 30 invited lectures; and has received awards for his research contributions from distinguished professional organizations such as the European Crohn’s and Colitis Organization (ECCO), the American Gastroenterological Association (AGA), the Crohn’s and Colitis Foundation (CCF) and United European Gastroenterology (UEG) association.

 

Ethos

“Just like you have to climb the mountain in order to see the view, doing scientific research requires inquisitiveness, adaptiveness and a team approach to overcome hurdles in order to reach the objective.”


Christopher Ma

Medical Director

Christopher Ma

Medical Director

Christopher supports medical R&D projects.

 

Background

Christopher has an MD (University of Calgary 2012), an Internal Medicine residency (University of Alberta), Adult Gastroenterology training (University of Calgary), Advanced IBD Fellowships (University of Calgary and Western University), Robarts IBD Clinical Trials Fellowship (2018) and MPH in Epidemiology (Harvard University 2019).

 

 

Achievements

<nil>

 

Ethos

“Teamwork is everything.”



Guangyong (GY) Zou

PhD - Biostatistician Director

After completing PhDs in Biostatistics and Plant Science from the University of Connecticut, GY joined Alimentiv in September 2002. He is also a full professor at Western University.

Background

GY oversees statistical support for academic R&D programs, as well as Alimentiv IBD clinical research.

He has over 20 years of experience designing and analyzing clinical trials, including cluster randomization trials. His research has primarily focused on development and evaluation of statistical methods for medical research. At Alimentiv, he’s also researching endpoint development and validation, larger-scale effectiveness research and strategy trials.

He has published over 150 peer-reviewed articles, many of which have impacted medical and epidemiologic research. A single-authored 2004 article on regression models for estimating risk ratios has already received close to 3,000 citations.

Achievements

He wrote a 2004 paper on estimation of risk ratios that’s been cited close to 5,000 times, and a 2012 paper the company uses to design reliability studies.

Ethos

“Results are only as good as the statistical methodology used to obtain them. My goal is to continuously create good statistical methodology for medical research.”



Niels Vande Casteele

Director Precision Medicine

Dr. Vande Casteele established the precision medicine group where he oversees the development, validation and operationalization of clinical pharmacology & translational medicine research tools to ascertain efficient drug development.

 

Background

Dr. Vande Casteele holds a Bachelor in Pharmaceutical Sciences and Masters in Drug Design and Development from the University of Leuven, Belgium. He performed research in the field of Molecular Biology at the Institute of Medical Sciences, University of Aberdeen, Scotland, and in the field of Immunology at Sanquin, University of Amsterdam, the Netherlands. He obtained his Ph.D. in Pharmaceutical Sciences entitled “Optimizing anti-TNF therapy in inflammatory bowel disease patients, a step towards personalized dosing” at the University of Leuven, Belgium.

 

Dr. Vande Casteele currently holds an appointment as Assistant Professor of Medicine at the University of California San Diego, United States, where he teaches a course on Biologics and Biosimilars Drug Development. His main research efforts focus on clinical pharmacology and translational medicine of small and large molecules used in the treatment of chronic inflammatory diseases, with an emphasis on characterizing pharmacokinetics and pharmacodynamics in relation to treatment outcomes in clinical practice and drug development.

 

Achievements

Dr. Vande Casteele has published over 100 peer reviewed research articles and book chapters; has given over 30 invited lectures; and has received awards for his research contributions from distinguished professional organizations such as the European Crohn’s and Colitis Organization (ECCO), the American Gastroenterological Association (AGA), the Crohn’s and Colitis Foundation (CCF) and United European Gastroenterology (UEG) association.

 

Ethos

“Just like you have to climb the mountain in order to see the view, doing scientific research requires inquisitiveness, adaptiveness and a team approach to overcome hurdles in order to reach the objective.”



Christopher Ma

Medical Director

Christopher supports medical R&D projects.

 

Background

Christopher has an MD (University of Calgary 2012), an Internal Medicine residency (University of Alberta), Adult Gastroenterology training (University of Calgary), Advanced IBD Fellowships (University of Calgary and Western University), Robarts IBD Clinical Trials Fellowship (2018) and MPH in Epidemiology (Harvard University 2019).

 

 

Achievements

<nil>

 

Ethos

“Teamwork is everything.”


Vipul Jairath

Vice President for Medical Research and Development

Vipul Jairath

Vice President for Medical Research and Development

Vipul oversees the global Medical R&D initiatives and services. In conjunction with the executive team and senior medical advisors, he assumes overall responsibility for research strategy, as well as performance of the organization’s Medical R&D services including medical operations, medical imaging, precision medicine, medical writing, medical monitoring, medical/biostatics advisory collaborations and IBD fellowships. He also provides medical oversight for the design of clinical trials, protocol development and imaging R&D endpoints. Vipul was previously Director of Academic Research and Development (2016-19).

Background

Dr Jairath obtained his BSc (Pharmacology) and Medical Degree from the University of Leeds (UK), DPhil (PhD) in Clinical Medicine from the University of Oxford and post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine. He is Professor of Medicine at the Schulich School of Medicine and Dentistry, and holder of the John and Susan McDonald Endowed Chair in Inflammatory Bowel Disease (IBD) at Western University.

His specialist clinical training in Gastroenterology was completed in London and Oxford, and he holds specialist certification in both Ontario and the UK. Prior to moving to Western in 2016, he was a National Institute for Health Research Clinical Trials Fellow at the Oxford Clinical Trials Research Unit and Consultant Gastroenterologist at Oxford University hospitals.

He is a practising gastroenterologist and specialist in inflammatory bowel disease, and his research interests in clinical therapeutics for IBD include design of clinical trials, development and validation of outcome measures for use in clinical trials, patient reported outcome measures and prediction modelling for response to therapy.

Achievements

Vipul has driven the development and validation of several novel indices for use in IBD clinical trials, like the UC-100 and the novel patient reported outcome measures, SIQ-UC and SIQ-CD. In addition, he was instrumental to the delivery of the REACT2 trial and to the design of the VERDICT trial, both of which are important clinical practice questions for patients with Crohn’s Disease and Ulcerative Colitis, respectively.

Ethos

“We are what we repeatedly do. Excellence, then, is not an act, but a habit.” — Aristotle



Vipul Jairath

Vice President for Medical Research and Development

Vipul oversees the global Medical R&D initiatives and services. In conjunction with the executive team and senior medical advisors, he assumes overall responsibility for research strategy, as well as performance of the organization’s Medical R&D services including medical operations, medical imaging, precision medicine, medical writing, medical monitoring, medical/biostatics advisory collaborations and IBD fellowships. He also provides medical oversight for the design of clinical trials, protocol development and imaging R&D endpoints. Vipul was previously Director of Academic Research and Development (2016-19).

Background

Dr Jairath obtained his BSc (Pharmacology) and Medical Degree from the University of Leeds (UK), DPhil (PhD) in Clinical Medicine from the University of Oxford and post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine. He is Professor of Medicine at the Schulich School of Medicine and Dentistry, and holder of the John and Susan McDonald Endowed Chair in Inflammatory Bowel Disease (IBD) at Western University.

His specialist clinical training in Gastroenterology was completed in London and Oxford, and he holds specialist certification in both Ontario and the UK. Prior to moving to Western in 2016, he was a National Institute for Health Research Clinical Trials Fellow at the Oxford Clinical Trials Research Unit and Consultant Gastroenterologist at Oxford University hospitals.

He is a practising gastroenterologist and specialist in inflammatory bowel disease, and his research interests in clinical therapeutics for IBD include design of clinical trials, development and validation of outcome measures for use in clinical trials, patient reported outcome measures and prediction modelling for response to therapy.

Achievements

Vipul has driven the development and validation of several novel indices for use in IBD clinical trials, like the UC-100 and the novel patient reported outcome measures, SIQ-UC and SIQ-CD. In addition, he was instrumental to the delivery of the REACT2 trial and to the design of the VERDICT trial, both of which are important clinical practice questions for patients with Crohn’s Disease and Ulcerative Colitis, respectively.

Ethos

“We are what we repeatedly do. Excellence, then, is not an act, but a habit.” — Aristotle